GLP-1 medicines show benefits beyond weight loss
Recent findings indicate that GLP-1 medicines, originally developed for weight loss, may also offer significant health benefits unrelated to weight reduction, reports BritPanorama.
While many patients experience noticeable weight loss with drugs like Wegovy and Zepbound, about 10 to 15% of users do not achieve substantial results, categorized as “non-responders.” New research suggests that genetic factors might influence these outcomes. Furthermore, studies have indicated that GLP-1 medicines could reduce the risk of heart attacks and strokes, and potentially improve outcomes in heart failure, even in patients who do not lose weight—or in some cases, may even gain weight.
A focus of recent studies has been on how GLP-1 treatments, particularly Wegovy, can improve liver health. The U.S. Food and Drug Administration approved Wegovy in August for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting approximately 6% of U.S. adults. Clinical trials have shown that the drug can significantly enhance liver disease markers.
Dr. Daniel Drucker, a leading researcher in GLP-1 therapy, stated that while weight loss has traditionally been viewed as the primary benefit of these treatments, emerging evidence suggests that improvements in metabolic conditions could occur independently of weight changes. Drucker argues that health insurers and government programs should reassess the criteria they use to evaluate these medicines, advocating for broader consideration of their therapeutic benefits across various serious diseases instead of focusing solely on weight reduction.
Dr. Jody Dushay, who prescribes GLP-1 medications, estimates that 5 to 8% of her patients are non-responders in terms of weight loss. She emphasized the importance of looking for other benefits from these medications, particularly as their approved uses expand.
Understanding the mechanisms behind GLP-1 benefits
A study led by Drucker sought to explain how semaglutide improves liver health, despite weight non-responsiveness in some patients. By eliminating GLP-1 receptors in specific mouse populations, the team observed that hepatic benefits were evident even without weight loss. These findings highlight a unique population of cells in the liver that respond to GLP-1, leading to reduced inflammation and improved liver health.
While the promising results were achieved in rodent models, Dr. Harlan Krumholz from Yale viewed the study as significant, noting that the mechanisms demonstrated in mice could inform further understanding of human health outcomes. However, he cautioned that further confirmation in human trials is necessary.
The inflammatory response and expanded applications
GLP-1 therapies are thought to modulate inflammation, which may underlie their beneficial effects for heart conditions and even kidney disease, irrespective of induced weight loss. A 2024 cardiovascular trial involving Wegovy found that the risk reduction for heart attacks or strokes appeared independent of patients’ weight loss outcomes.
Professor John Deanfield from University College London highlighted the need for further exploration into the medications’ positive effects on blood sugar, blood pressure, and overall cardiovascular health. However, Dr. Drucker noted that meaningful weight reduction remains a significant factor in managing many conditions, including arthritis and sleep apnea.
The evolving evidence suggests that these medications could be tailored to optimize outcomes for patients without solely prioritizing weight loss. Dr. Drucker pointed out that understanding the precise role of these drugs across various conditions is essential for guiding treatment approaches moving forward.
This ongoing research continues to refine the understanding of GLP-1 therapies, suggesting a broader range of therapeutic potentials that extend beyond weight management. As the landscape of metabolic disease treatment evolves, so too will the conversation surrounding the appropriate applications of these drugs.
